Forest Hills Partners

Forest Hills Lab is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease. The company's research focuses on the Nurr1 receptor, a key transcription factor essential for the development and maintenance of dopaminergic neurons. Its lead program, FHL-001, is a small molecule Nurr1 agonist currently being evaluated in Phase 2 clinical trials for the treatment of Parkinson's disease. Beyond Parkinson's, Forest Hills Lab is exploring the potential of Nurr1 activation in other conditions, including Alzheimer's disease and neuroinflammation. By targeting the underlying biological drivers of neuronal loss, the company aims to provide transformative treatments for patients suffering from debilitating CNS diseases.